GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Alterity Therapeutics ATH.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.30

+13.21%

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in AUD, from our data supplier.

FY2025

Revenue

A$446,300

FY2016FY2025

Net income

−A$12.1m

FY2016FY2025

Free cash flow

−A$11.5m

FY2016FY2025

Shareholders' equity

—

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueA$446,300A$268,400A$16,400A$2,500A$20,700A$17,100A$108,500A$201,200A$132,400A$142,700
Research and developmentA$14.4mA$18.6mA$13.2mA$14.7mA$12.3mA$10.1mA$13.0mA$6.7mA$5.7mA$9.6m
Operating income−A$14.2m−A$19.3m−A$14.6m−A$16.0m−A$15.4m−A$13.9m−A$12.7m−A$8.0m−A$6.9m−A$8.6m
Net income−A$12.1m−A$19.1m−A$13.8m−A$12.8m−A$15.3m−A$13.5m−A$12.3m−A$8.3m−A$7.5m−A$7.7m
Diluted earnings per share-0.00-0.01-0.01-0.01-0.01-0.02-0.02-0.02-0.01-0.01

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets——A$27.3mA$41.4mA$33.6mA$9.9mA$19.9mA$18.7mA$25.3mA$33.7m
Cash and short-term investments——A$15.8mA$34.8mA$28.1mA$9.2mA$14.4mA$15.2mA$21.9mA$28.6m
Total liabilities——A$4.5mA$5.9mA$3.1mA$2.8mA$3.4mA$2.6mA$1.6mA$2.4m
Debt——A$210,000A$117,500A$65,700A$33,800————
Shareholders' equity——A$22.8mA$35.5mA$30.5mA$7.2mA$16.6mA$16.1mA$23.7mA$31.4m
Shares outstanding6,397m3,649m2,428m2,406m1,697m895m616m533m534m534m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−A$11.5m−A$12.6m−A$20.0m−A$12.3m−A$17.3m−A$9.4m−A$14.0m−A$6.2m−A$5.9m−A$7.3m
Capital spending—−A$5,700−A$7,300−A$89,100−A$10,500−A$16,700−A$7,000−A$62,400−A$27,900−A$2,300
Free cash flow−A$11.5m−A$12.6m−A$20.0m−A$12.4m−A$17.3m−A$9.4m−A$14.0m−A$6.3m−A$5.9m−A$7.3m

Latest quarters

By quarter end

Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Mar 2023Dec 2022Sept 2022
RevenueA$335,000A$111,300A$150,000A$118,400A$5,100A$765,000A$11,400A$1.2m
Operating income−A$7.1m−A$7.1m−A$12.8m−A$6.5m−A$7.8m−A$3.1m−A$10.8m−A$4.2m
Net income−A$5.0m−A$7.2m−A$12.6m−A$6.5m−A$5.8m−A$2.9m−A$8.0m−A$4.0m
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Total assetsA$46.0mA$10.5mA$19.2mA$22.2mA$27.3mA$27.3mA$33.4mA$33.4m
Cash and short-term investmentsA$33.2mA$4.5mA$12.6mA$12.3mA$15.8mA$15.8mA$25.3mA$25.3m
DebtA$88,600A$43,100A$51,900A$76,500A$103,200A$103,000A$29,300A$29,000
Shareholders' equityA$42.4mA$7.8mA$13.8mA$17.6mA$22.8mA$22.8mA$28.1mA$28.1m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue463.1%92.0%9.7%
Operating income-3.8%0.4%-1.8%
Net income-1.8%-2.0%7.5%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-4694.8%-8741.7%-12109.5%-9561.2%
Net margin-4375.4%-7896.0%-11238.2%-8379.1%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-210.6-76.3-61.5-53.5-66.5-58.9-28.5-60.8-143.6-90.8

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.